<p>In randomized, double-blind trial, no difference seen in scores for agitated behaviors at 12 weeks with mirtazapine versus placebo</p>
<p>Does not improve primary outcome, but did improve performance on certain cognitive tasks in those with epileptiform activity</p>
<p>Overall, 92.2, 91.0, and 85.5 percent of Medicare beneficiaries with ADRDs, Alzheimer disease, and MCI met at least one of the exclusion criteria</p>
<p>Risk for AD increased for parents of individuals with ADHD; associations attenuated with decreasing genetic relatedness</p>
<p>Individual doctors can prescribe Aduhelm, but patients would have to go elsewhere to receive the drug via infusion</p>
<p>Taking up reading, puzzles, and games even in one's 80s may provide cognitive protection</p>
<p>CMS says a final decision on coverage is not likely until next spring</p>
<p>Request follows reports that Biogen and the FDA held off-the-books meetings before the drug's approval that may have violated FDA protocol</p>
<p>Major changes to prescribing instructions are rare, especially so soon after approval; change could curb the drug's use</p>
<p>FDA approved Aduhelm earlier this month, despite advisory committee's conclusion that there was not enough evidence to support its effectiveness</p>